Navigation Links
Telomerase Presentations at the AACR 2007 Annual Meeting

of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, diabetes and HIV/AIDS. The company is advancing an anti-cancer drug and a cancer vaccine that target the enzyme telomerase through multiple clinical trials. Geron is also the world leader in the development of human embryonic stem cell-based therapeutics, with its spinal cord injury treatment anticipated to be the first product to enter clinical development. For more information, visit www.geron.com.

This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Geron's telomerase technology constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Geron's periodic reports, including the annual report on Form 10-K for the year ended December 31, 2006.

Contact

Noonan Russo
David Schull, 858-717-2310 (Media)
david.schull@eurorscg.com
Matthew Haines, 212-845-4235 (Investors)
matthew.haines@eurorscg.com
or
Geron
David L. Greenwood, Chief Financial Officer, 650-473-7765
info@ger
'"/>





Page: 1 2 3 4

Related medicine technology :

1. Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits
2. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
3. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
4. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
6. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
7. Inspire Announces Presentations at Two European Scientific Conferences
8. Presentations at 2007 European Stroke Congress Highlights New Direction for Viprinex (ancrod)
9. IDM Pharma Announces UVIDEM(R) and EP-2101 Data Presentations at 2007 ASCO Annual Meeting
10. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
11. Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2007 American Society of Clinical Oncology Annual Meeting

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Telomerase Presentations the AACR Annual Meeting
(Date:11/6/2009).... 6 Boston Scientific Co...s reached an agreement in principle with the U.S. ...isories issued by its Guidant subsidiary in 2005. ...ior to Boston Scientific,s 2006 acquisition of Gui...osed an investigation by the U.S. Attorney,s Offic...
(Date:11/6/2009)...PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals,... on Tuesday, November 10, 2009 at 8:30 a.m. EST to...and business outlook for the remainder of 2009. R..., will host the call. Keryx will announce its fin...to be issued prior to the call. ,, In order to ...
(Date:11/6/2009)...RNewswire-FirstCall/ -- Caraco Pharmaceutical Labo...orolac tromethamine ophthalmic solution, 0.5% foll...dministration (FDA) for Sun Pharma,s Abbreviated N...; opthalmic solution on the first day following pa...rapeutically equivalent to Acular® Ophthalmic...
Breaking Medicine Technology:Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 2Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 3Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 4Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 5Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 6Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 7Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 8Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 9Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 10Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 11Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 12Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 13Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 14Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 15Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 16Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 17Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST 2Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Opthalmic Solution 22009 John M Eisenberg Patient Safety and Quality Award Recipients Announced 57801 12009 John M Eisenberg Patient Safety and Quality Award Recipients Announced 57801 22009 John M Eisenberg Patient Safety and Quality Award Recipients Announced 57801 32009 John M Eisenberg Patient Safety and Quality Award Recipients Announced 57801 4SC Johnson Joins Conservation Internationals Team Earth a Worldwide Sustainability Movement As One of the Founding Members 57799 1SC Johnson Joins Conservation Internationals Team Earth a Worldwide Sustainability Movement As One of the Founding Members 57799 2SC Johnson Joins Conservation Internationals Team Earth a Worldwide Sustainability Movement As One of the Founding Members 57799 3US Farms Inc Announces Membership to International Aloe Science Council Inc 57797 1US Farms Inc Announces Membership to International Aloe Science Council Inc 57797 2
...y prospectively planned 5-year study to show long ...t -, MONTREAL, Sept. 20 Bayer HealthCare Pharmac...NEFIT (BEtaseron in Newly Emerging,multiple sclero...y,initiation of Betaseron(R) (interferon beta-1b) ...e of multiple sclerosis (MS) significantly delayed...
...Novavax, Inc.,(Nasdaq: NVAX ) a clinical-stage va...hvi, President and Chief Executive Officer, will b...Conference in New York, NY. The,conference is bein...tel.,Dr. Singhvi will be presenting Thursday, Sept...hvi will provide an overview of the company,s,stra...
Other Medicine Technology:Five-Year Data Confirm That Early Treatment with Betaseron(R) at First Sign of Disease Can Delay Progression to MS 2Five-Year Data Confirm That Early Treatment with Betaseron(R) at First Sign of Disease Can Delay Progression to MS 3Five-Year Data Confirm That Early Treatment with Betaseron(R) at First Sign of Disease Can Delay Progression to MS 4Five-Year Data Confirm That Early Treatment with Betaseron(R) at First Sign of Disease Can Delay Progression to MS 5
(Date:11/7/2009)...WASHINGTON , Nov. 7 ...y in support of H.R. 3962, the Affordable Health C...egislation later tonight. Below are the Speaker,s...know, is an historic moment for our nation and for... of every party and political philosophy -- as far...
(Date:11/7/2009)... Jacquelyn T. Coleman (CT), David A. Cook (GA), Lo.... Tarver (LA) Honored ,, CHICAGO, Nov. 7 /PRNe...tion (AMA) today presented five medical society ex...heir contributions to the goals and ideals of the ...he AMA,s semi-annual policy making meeting in Hous...
(Date:11/7/2009)...WASHINGTON, Nov. 7 With..., antichoice extremists are holding the entire bil...ey are demanding that the bill go far beyond the s...ncorporated into the original bill. In an outrage...rly Saturday afternoon, antichoice Democrats are d...
(Date:11/7/2009)...WASHINGTON, Nov. 7 Spea...ss availability this afternoon following a Democra...n Caucus Room. Below are the Speaker,s opening re..., it was a great occasion for us to receive the Pr...ill be making history with our vote and making pro...
(Date:11/7/2009)...should not assume that all youth will rebel, exper...s) -- Teens are more likely to behave badly if the...und. , "Parents who believe they are simply being ...illing prophecy," Christy Buchanan, a psychology p...f the study, said in a university news release. "N...
Breaking Medicine News(10 mins):Health News:Pelosi: Health Legislation Founded on Key Principles for a Healthier America: Innovation, Competition and Prevention 2Health News:Pelosi: Health Legislation Founded on Key Principles for a Healthier America: Innovation, Competition and Prevention 3Health News:Pelosi: Health Legislation Founded on Key Principles for a Healthier America: Innovation, Competition and Prevention 4Health News:AMA Honors Medical Society Executives 2Health News:Pelosi Remarks Following House Democrats' Meeting with President Obama 2Health News:Bad-Behaving Teens May Be Living Up to Expectations 2
...s given the analysis, report says , MONDAY, Aug. 2...ic obstructive pulmonary disease (COPD) is not use...that found that only one-third of patients diagnos.... , "Without proper testing, both under-diagnosi...
...y researchers have first insight into how Huntingt...be published online in the British Journal, Human ...e are exciting results by the McMaster team, said ...he huntingtin protein has been known for almost 20...
...finds that implantable cardioverter defibrillators...r adults with left ventricular systolic dysfunctio...ized controlled trials that reported on mortality ...unction by 20 percent. This reduction came mostly ...
...7 Computer analysis of existing drugs may be key ...esistant pathogens like deadly tuberculosis strain...he use of such emergency discovery technology coul... Chemical Society. , Drug repurposing or reprofil...
... anthocyanin molecules could lead to new treatment...-- Compounds called anthocyanins, which give color...s, may help protect against colon cancer, an Ohio ...slow the growth of colon cancer cells. The team al...
...en that may be able to spot teens prone to violenc...- What motivates some teens to gun down fellow stu... , Perhaps a characteristic called "cynical shynes...ly, Virginia Tech, according to researchers who we...
Other Medicine News:Health News:A new molecular zip code, and a new drug target for Huntington's disease 2Health News:A new molecular zip code, and a new drug target for Huntington's disease 3Health News:Computers help chemists fight emerging infections 2Health News:Computers help chemists fight emerging infections 3Health News:Does Pathological Shyness Make for School Shooters? 2Health News:Does Pathological Shyness Make for School Shooters? 3Health News:Does Pathological Shyness Make for School Shooters? 4
Drug Facts - Silver (A to Z Drug Facts with Auto-Updates)
Drug Facts - Platinum (A to Z, Natural Products and Drug Interaction)
Drug Facts - Gold (A to Z Drugs and Drug Interaction)
... Guide to Drug Interaction Principles is the numbe...sly for clinicians. , An understanding of drug in... medicine. Since publication of the first edition ...macopoeia - coupled with prolonged human life span...
Medicine Products: